BioDelivery Sciences International (BDSI) Shares Up 6.9%

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) shot up 6.9% on Friday . The stock traded as high as $3.15 and last traded at $3.10. 1,849,957 shares were traded during mid-day trading, an increase of 290% from the average session volume of 473,912 shares. The stock had previously closed at $2.90.

Several brokerages have recently weighed in on BDSI. HC Wainwright set a $4.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a report on Friday, April 13th. Roth Capital set a $4.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a report on Friday, May 11th. Cantor Fitzgerald set a $5.00 price target on BioDelivery Sciences International and gave the stock a “buy” rating in a report on Monday, May 7th. Finally, ValuEngine upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $4.07.

The company has a debt-to-equity ratio of 35.82, a quick ratio of 1.13 and a current ratio of 1.40.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings data on Thursday, May 10th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.03. BioDelivery Sciences International had a negative return on equity of 388.58% and a negative net margin of 122.75%. The company had revenue of $11.28 million for the quarter, compared to analysts’ expectations of $10.77 million. research analysts anticipate that BioDelivery Sciences International, Inc. will post -0.68 EPS for the current fiscal year.

In related news, Director Mark A. Sirgo sold 100,000 shares of the stock in a transaction that occurred on Tuesday, April 10th. The stock was sold at an average price of $2.06, for a total value of $206,000.00. Following the transaction, the director now owns 2,585,966 shares of the company’s stock, valued at $5,327,089.96. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Paolantonio Ernest Robert De sold 64,155 shares of the stock in a transaction that occurred on Friday, April 6th. The stock was sold at an average price of $2.09, for a total value of $134,083.95. Following the completion of the transaction, the chief financial officer now directly owns 97,731 shares in the company, valued at approximately $204,257.79. The disclosure for this sale can be found here. 9.00% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in BDSI. Two Sigma Investments LP bought a new position in BioDelivery Sciences International in the fourth quarter worth approximately $166,000. Wells Fargo & Company MN grew its stake in BioDelivery Sciences International by 88.9% in the fourth quarter. Wells Fargo & Company MN now owns 67,081 shares of the specialty pharmaceutical company’s stock worth $198,000 after purchasing an additional 31,575 shares in the last quarter. BlueCrest Capital Management Ltd bought a new position in BioDelivery Sciences International in the fourth quarter worth approximately $201,000. Goldman Sachs Group Inc. bought a new position in BioDelivery Sciences International in the fourth quarter worth approximately $223,000. Finally, Knott David M bought a new position in BioDelivery Sciences International in the first quarter worth approximately $270,000. 46.13% of the stock is currently owned by institutional investors.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply